Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 4 (2007), Issue 12 (December)

1. Transforming growth factor-beta 1 gene polymorphisms and expression in the blood of prostate cancer patients.
   Cancer Invest, 25(8): 726-32. [Abstract] [Full-text]
2. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts.
   J Natl Cancer Inst, 99(23): 1793-800. [Abstract] [Full-text]
3. p-Dodecylaminophenol derived from the synthetic retinoid, fenretinide: antitumor efficacy in vitro and in vivo against human prostate cancer and mechanism of action.
   Int J Cancer, 122(3): 689-98. [Abstract] [Full-text]
4. Caveolin-1 secreting LNCaP cells induce tumor growth of caveolin-1 negative LNCaP cells in vivo.
   Int J Cancer, 122(3): 520-5. [Abstract] [Full-text]
5. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
   Int J Cancer, 122(3): 509-19. [Abstract] [Full-text]
6. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients.
   Int J Cancer, 122(3): 595-602. [Abstract] [Full-text]
7. 2-Methoxyestradiol modulates beta-catenin in prostate cancer cells: a possible mediator of 2-methoxyestradiol-induced inhibition of cell growth.
   Int J Cancer, 122(3): 567-71. [Abstract] [Full-text]
8. The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells.
   Int J Cancer, 122(3): 558-66. [Abstract] [Full-text]
9. Inflammation and prostate cancer: a future target for prevention and therapy?
   Urol Clin North Am, 35(1): 117-30; vii. [Abstract] [Full-text]
10. Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models.
    Nanomedicine, 3(4): 281-96. [Abstract] [Full-text]
11. Monoclonal antibody therapy for prostate cancer.
    Handb Exp Pharmacol. [Abstract] [Full-text]
12. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells.
    Proc Natl Acad Sci U S A, 104(50): 19983-8. [Abstract] [Full-text]
13. Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose.
    Br J Radiol, 81(961): 59-68. [Abstract] [Full-text]
14. Green tea consumption and prostate cancer risk in Japanese men: a prospective study.
    Am J Epidemiol, 167(1): 71-7. [Abstract] [Full-text]
15. The discovery of prostate-specific antigen.
    BJU Int, 101(1): 5-10. [Abstract] [Full-text]
16. Interpreting trends in prostate cancer incidence and mortality in the five Nordic countries.
    J Natl Cancer Inst, 99(24): 1881-7. [Abstract] [Full-text]
17. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.
    J Natl Cancer Inst, 99(24): 1836-44. [Abstract] [Full-text]
18. Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer.
    Cancer Res, 67(24): 11970-9. [Abstract] [Full-text]
19. Targeting Cdc37 inhibits multiple signaling pathways and induces growth arrest in prostate cancer cells.
    Cancer Res, 67(24): 11942-50. [Abstract] [Full-text]
20. BRCA1 mutations and prostate cancer in Poland.
    Eur J Cancer Prev, 17(1): 62-6. [Abstract] [Full-text]
21. Protective effect of Acticoa powder, a cocoa polyphenolic extract, on prostate carcinogenesis in Wistar-Unilever rats.
    Eur J Cancer Prev, 17(1): 54-61. [Abstract] [Full-text]
22. Immunization with a recombinant GnRH vaccine conjugated to heat shock protein 65 inhibits tumor growth in orthotopic prostate cancer mouse model.
    Cancer Lett, 259(2): 240-50. [Abstract] [Full-text]
23. Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells.
    Mol Pharmacol, 73(1): 235-42. [Abstract] [Full-text]
24. Relevance of a new rat model of osteoblastic metastases from prostate carcinoma for preclinical studies using zoledronic acid.
    Int J Cancer, 122(4): 751-60. [Abstract] [Full-text]
25. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.
    Int J Cancer, 122(4): 952-6. [Abstract] [Full-text]
26. Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia.
    Int J Cancer, 122(4): 864-70. [Abstract] [Full-text]
27. Screening for prostate cancer in Dutch hereditary prostate cancer families.
    Int J Cancer, 122(4): 871-6. [Abstract] [Full-text]
28. Diet and prostate cancer risk reduction.
    Expert Rev Anticancer Ther, 8(1): 43-50. [Abstract] [Full-text]
29. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer.
    Expert Rev Anticancer Ther, 8(1): 33-42. [Abstract] [Full-text]
30. Pure and robotic-assisted laparoscopic radical prostatectomy: technology and techniques merge to improve outcomes.
    Expert Rev Anticancer Ther, 8(1): 15-9. [Abstract] [Full-text]
31. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines.
    Prostate, 68(2): 210-22. [Abstract] [Full-text]
32. Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent.
    Prostate, 68(2): 183-9. [Abstract] [Full-text]
33. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
    Prostate, 68(2): 190-9. [Abstract] [Full-text]
34. Altered expression of genes regulating angiogenesis in experimental androgen-independent prostate cancer.
    Prostate, 68(2): 161-70. [Abstract] [Full-text]
35. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis.
    Prostate, 68(2): 200-9. [Abstract] [Full-text]
36. Quantitative, spatial resolution of the epigenetic field effect in prostate cancer.
    Prostate, 68(2): 152-60. [Abstract] [Full-text]
37. Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice.
    Prostate, 68(2): 129-38. [Abstract] [Full-text]
38. Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation.
    Prostate, 68(2): 139-51. [Abstract] [Full-text]
39. SUMOylation of pontin chromatin-remodeling complex reveals a signal integration code in prostate cancer cells.
    Proc Natl Acad Sci U S A, 104(52): 20793-8. [Abstract] [Full-text]

© 2004-2008 Prostate Cancer Research Today. All Rights Reserved.